2022 Safadi Lecture: Emerging Gene Therapies for the Central Nervous System
Learn more at our website!
After this activity, participants will be able to:
- Describe current gene therapy tools to treat brain diseases;
- Identify gain-of-function diseases, which are caused by the ectopic or increased activity of the mutated gene product;
- Recall recent improvements in gene vectors and their design that will result in improved outcomes for patients with brain diseases.
Learners can attend this event in-person or virtually. For questions about the event, contact Daniel Nava via e-mail.
WANT TO KNOW MORE?
ACCESSIBILITY The University of Chicago is committed to providing equal access appropriate to need and circumstances and complies fully with legal requirements of the Americans with Disabilities Act. If you are in need of special accommodation, please contact Amy Johnson via email at email@example.com.
The University of Chicago reserves the right to cancel or postpone this conference due to unforeseen circumstances. In the unlikely event this activity must be cancelled or postponed, the registration fee will be refunded; however, The University of Chicago is not responsible for any related costs, charges, or expenses to participants, including fees assessed by airline/travel/lodging agencies.
Arthur V. Meigs Chair in Pediatrics
Director, Raymond G Perelman Center for
Cellular and Molecular Therapeutics
Chief Scientific Strategy Officer
Children’s Hospital of Philadelphia
Professor, Pathology and Laboratory Medicine
University of Pennsylvania
As a provider accredited by the ACCME, The University of Chicago Pritzker School of Medicine asks everyone in a position to control the content of an education activity to disclose all financial relationships with any ineligible companies. This includes any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Financial relationships are relevant if a financial relationship, in any amount, exists between the person in control of content and an ineligible company during the past 24 months, and the content of the education is related to the products of an ineligible company with whom the person has a financial relationship. Mechanisms are in place to identify and mitigate any relevant financial relationships prior to the start of the activity.
Additionally, The University of Chicago Pritzker School of Medicine requires Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration at first mention and where appropriate in the content.
The University of Chicago Pritzker School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Other healthcare professionals will receive a Certificate of Participation. For information on the applicability and acceptance of Certificates of Participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME, please consult your professional licensing board.
Please Note: The credit claiming process will close three months after the conference end date. Requests to claim credit after three months will be subject to additional fees.